Skip to main content

Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products

by Alexandra Agraz | Feb 10, 2026
Close-up of a large pile of white round pills stamped with GLP-1.
Photo Source: Adobe Stock Image

Novo Nordisk has filed a federal lawsuit accusing telehealth company Hims & Hers Health of infringing its semaglutide patent by marketing and selling compounded weight loss drugs. The case, filed in the U.S. District Court for the District of Delaware, challenges whether Hims’ compounded semaglutide products unlawfully use technology protected by Novo Nordisk’s FDA-approved medicines, according to court filings.

The lawsuit was brought by Novo Nordisk A/S and Novo Nordisk Inc. against Hims & Hers Health, Inc. and its subsidiary Hims, Inc., both Delaware corporations. Novo Nordisk claims the telehealth company has offered compounded semaglutide products nationwide through its online platform and affiliated pharmacies without authorization, despite Novo Nordisk holding exclusive rights to the compound used in its diabetes and weight loss drugs Ozempic, Wegovy, and Rybelsus.

Hims & Hers is a publicly traded telehealth company that provides online medical consultations and prescription treatments for a range of conditions, including hair loss, mental health, sexual wellness, and weight management. In recent years, the company expanded into weight loss services by offering compounded glucagon-like peptide-1 treatments amid rising demand for drugs such as Ozempic and Wegovy. According to the Civil ComplaintA complaint is the formal pleading that generally begins a civil lawsuit. It identifies the parties, states the legal and factual basis for the plaintiff’s claims, explains why the court has authority to hear the case, and asks the court for a specific form of relief.Read more →, the company markets these medications directly to consumers through its websites and coordinates fulfillment through partner pharmacies.

The compound at the center of the dispute is semaglutide, a GLP-1 receptor agonist that helps regulate blood sugar and appetite. Novo Nordisk states that it spent decades conducting research and investing billions of dollars to develop semaglutide and bring its products to market through the Food and Drug Administration’s approval process. That process requires extensive testing and regulatory review to ensure that medicines meet federal standards for safety, effectiveness, and manufacturing quality.

Novo Nordisk argues that Hims attempted to bypass that regulatory framework by offering compounded versions of semaglutide that have not been reviewed or approved by the FDA. The complaint points to statements on Hims’ website acknowledging that its compounded products are not evaluated for safety, effectiveness, or quality by the agency. Novo Nordisk claims this approach exceeds the limited scope of drug compounding under federal law and infringes its intellectual property rights.

Novo Nordisk’s lawsuit rests on its claim that it holds exclusive patent rights covering semaglutide. Under federal patent law, the owner of a patented invention has the sole right to make, use, and sell that technology or to authorize others to do so. Novo Nordisk argues that by offering compounded products containing semaglutide without permission, Hims unlawfully used technology protected by those rights.

The case also turns on a legal distinction that often shapes disputes involving compounded drugs. Federal law permits pharmacies to compound medications in limited circumstances, such as when a patient requires a customized formulation. Novo Nordisk argues that those permissions do not override existing patent rights and do not allow companies to replicate a patented drug simply because demand is high or access is constrained.

Novo Nordisk also alleges induced infringement, a legal theory that applies when a company encourages or facilitates others to violate a patent. According to the complaint, Hims worked with pharmacies, medical providers, and patients to make and use the patented compound. Novo Nordisk points to the company’s role in directing how the medication is dispensed and used, including providing instructional materials, as evidence that Hims actively promoted the alleged infringement.

The lawsuit further alleges that the infringement was willful. According to court filings, Novo Nordisk notified Hims of the patent and its alleged infringement and sent a letter on February 8, 2026, demanding that the company stop its unauthorized use of the technology. Novo Nordisk claims that Hims continued offering the accused products after receiving that notice. If established, a finding of willful infringement can allow a court to award enhanced damages under federal patent law.

The court has not yet ruled on the claims.

Share This Article

If you found this article insightful, consider sharing it with your network.

Alexandra Agraz
Alexandra Agraz is a former Diplomatic Aide with firsthand experience in facilitating high-level international events, including the signing of critical economic and political agreements between the United States and Mexico. She holds dual associate degrees in Humanities, Social and Political Sciences, and Film, blending a diverse academic background in diplomacy, culture, and storytelling. This unique combination enables her to provide nuanced perspectives on global relations and cultural narratives.

Related Articles

Gloved medical professional holds an intravenous drug infusion bag in a clinical setting.

Drugmakers Sue to Block Trump Medicare Plan Tying Drug Costs to Lower Foreign Prices

The pharmaceutical industry’s leading trade group is suing the Trump administration over a new Medicare drug-pricing program that could lower out-of-pocket costs for some patients receiving expensive cancer, autoimmune, and other medications administered in medical settings.The Pharmaceutical Research and Manufacturers of America, or PhRMA, filed the lawsuit on October 7,... Read More about Drugmakers Sue to Block Trump Medicare Plan Tying Drug Costs to Lower Foreign Prices

A hand holding a smartphone displaying the "hims & hers" logo, with the brand's blurred name visible in the background.

Hims Sued Over Alleged Unwanted Prescription Subscriptions and Health Data Sharing

Federal and state regulators have sued Hims & Hers Health, alleging the telehealth company charged hundreds of thousands of consumers for prescription subscriptions without their informed consent and shared sensitive health information with advertising platforms despite promises that its service was private and discreet.The Federal Trade Commission, California, and the... Read More about Hims Sued Over Alleged Unwanted Prescription Subscriptions and Health Data Sharing

Blue-gloved hand holding a Novo Nordisk injection pen with the dose dial visible and the Novo Nordisk logo.

Novo Nordisk Must Face Investor Fraud Claims Over CagriSema Trial Disclosures

Novo Nordisk must face part of a securities fraud lawsuit accusing the drugmaker of misleading investors about dosing and tolerability in a late-stage clinical trial for CagriSema, after a federal judge allowed a narrower set of shareholder claims to move forward.U.S. District Judge Robert Kirsch in New Jersey ruled Tuesday... Read More about Novo Nordisk Must Face Investor Fraud Claims Over CagriSema Trial Disclosures

Sign for Novant Health at Forsyth Medical Center, displaying the center's address.

Staffing Company Sues Health Services Provider over $1.5M in Unpaid Services

The Illinois-based staffing agency Medix Staffing Solutions is suing an aggregate health services provider, Novo Health LLC and its affiliate companies for failure to pay for services rendered. The lawsuit was filed in the Northern District of Illinois earlier this month. The staffing agency provides staffing services to several... Read More about Staffing Company Sues Health Services Provider over $1.5M in Unpaid Services

Legal term

Search articles and Legalpedia

Subscribe to Newsletter